# Axoft

> Axoft is a Cambridge, Massachusetts neurotechnology company building implantable brain-computer interfaces (iBCIs) out of Fleuron, a proprietary material it claims is up to 10,000x softer than the polyimide used in conventional brain implants. By making electronics roughly as soft as brain tissue, Axoft aims to keep thousands of sensors in stable contact with single neurons for years instead of months - reducing scarring and signal loss - to diagnose and eventually treat disorders of consciousness, paralysis, and other neurological conditions. A Harvard spinout founded in 2021, it raised an oversubscribed $55M Series A in April 2026 and has run first-in-human studies in 11+ patients worldwide.

- **Founded:** 2021
- **Headquarters:** Cambridge, Massachusetts, United States
- **Founders:** Paul Le Floch (CEO & Co-Founder), Tianyang Ye (CTO & Co-Founder), Jia Liu (Co-Founder & Scientific Advisor)
- **Team size:** ~39 employees
- **Products:** Fleuron, Implantable Brain-Computer Interface (iBCI), Neural decoding software
- **Notable:** Granted FDA Breakthrough Device Designation (2022), Developed Fleuron, an ultra-soft material that doubles as a chip-fabrication photoresist, Completed first-in-human studies in 11+ patients across the US, Panama, and China

## Products & services

- **Fleuron** — A proprietary ultra-soft implant material up to 10,000x softer than polyimide and roughly 1,000,000x softer than silicon, while still functioning as a photoresist suitable for chip fabrication. ISO-10993 compliant and biocompatible; commercially available via an exclusive license agreement with Stanford University.
- **Implantable Brain-Computer Interface (iBCI)** — A bio-inspired neural probe carrying 1,000+ sensors on threads soft enough to mimic brain tissue. Axoft cites 32x more sensors per thread, 8x more region access, and over 60% reduced signal loss versus conventional rigid implants, enabling single-cell electrophysiology at scale.
- **Neural decoding software** — Multimodal deep-learning models that decode brain signals captured by the implant, aimed at measuring consciousness, recovery, and communication in patients.

## Achievements

- Granted FDA Breakthrough Device Designation (2022)
- Developed Fleuron, an ultra-soft material that doubles as a chip-fabrication photoresist
- Completed first-in-human studies in 11+ patients across the US, Panama, and China
- Raised an oversubscribed $55M Series A in April 2026 (over $60M+ total funding)
- Signed an exclusive Fleuron license agreement with Stanford University (2025)
- Founder Paul Le Floch named to Forbes 30 Under 30 (Science, 2021)

## Latest updates

- **2026-04** — Raised an oversubscribed $55M Series A led by C.P. Group Innovation to expand global clinical trials, advance US FDA approval, and build a GMP manufacturing facility in Cambridge.
- **2025-08** — Harvard Gazette profiled Axoft's scar-free soft brain implants and the Fleuron material's ability to host 1,000+ sensors.
- **2025-05** — Announced commercialization of Fleuron under an exclusive license agreement with Stanford University.
- **2022-10** — Publicly launched its brain implant technology and received FDA Breakthrough Device Designation.

## Links

- Website: https://axoft.us
- LinkedIn: https://www.linkedin.com/company/axoftus
- Twitter/X: https://twitter.com/axoft_us

---

Profile page: https://yespress.io/axoft
Published by YesPress — https://yespress.io
Last updated: 2026-06-07